MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection

Int J Immunogenet. 2005 Oct;32(5):269-71. doi: 10.1111/j.1744-313X.2005.00523.x.

Abstract

Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • CD4 Lymphocyte Count / methods
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / virology
  • HIV Infections / genetics
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Humans
  • Male
  • Matrix Metalloproteinase 7
  • Metalloendopeptidases / genetics
  • Metalloendopeptidases / immunology*
  • Middle Aged
  • Polymorphism, Genetic / genetics
  • Polymorphism, Genetic / immunology*
  • Viral Load* / methods

Substances

  • Anti-Retroviral Agents
  • Metalloendopeptidases
  • MMP7 protein, human
  • Matrix Metalloproteinase 7